A screening in melanoma cells by Manguso et al. (2017) found that the deletion of protein tyrosine phosphatase protein tyrosine phosphatase non-receptor type 2 (PTPN2) enhances interferon-γ-mediated antigen presentation and growth inhibition to improve the efficacy of immunotherapy. This evidence concerns the gene PTPN2 and melanoma.